Reference News Network, June 29 report - According to the Hong Kong South China Morning Post website, June 26 report, emerging Chinese drug innovation companies are joining their foreign competitors in using more artificial intelligence (AI) tools to reduce R&D costs and shorten commercialization cycles.
Analysts at JPMorgan Chase said that Nanjing GenScript Biotech is developing its own AI tools to identify and optimize promising candidate drugs based on protein sequences and therapeutic targets.
Shenzhen-based AI drug research company Insilico Medicine recently announced an agreement with US-based Pigeon Tree Company to develop candidate drugs for tumor, autoimmune diseases, and neurodegenerative disease-related targets selected by the latter, and Pigeon Tree Company will obtain the commercialization rights of these drugs.
Recently, Insilico Medicine published the results of Phase II trials of its candidate drug Rentosertib in the journal Nature Medicine, claiming it as the first clinical proof of concept for AI-powered drug discovery. The candidate drug is planned for the treatment of idiopathic pulmonary fibrosis, a chronic progressive disease characterized by scarring of lung tissue.
This is related to an industry expected to grow rapidly in the next decade. In a report in April, US Kocher Solutions stated that the market size for AI-assisted drug development is expected to reach $13 billion by 2032.
Netherlands-based AI infrastructure and software provider Nibio said that AI can process large amounts of data such as genetic and protein content of biological samples and clinical trial data faster and more accurately.
The global head of Nibio's healthcare and life sciences division, Ilya Burkov, said: "Previously, drug innovation was slow, expensive, and often stalled due to outdated infrastructure. AI platforms can help identify new targets and design promising new candidate drugs in as little as 18 months, which traditionally took 5 to 7 years."
Goldman Sachs said that although AI-assisted drug development is still a relatively new field, with no candidate projects yet commercialized, AI models have the potential to predict accurately, for example, translating animal trial results into human clinical applications.
Chen Zi Yi (音), head of Goldman Sachs Asia healthcare research, told an interview: "This is the biggest bottleneck, and where real disruptive results may emerge. AI is promising, full of hope and uncertainty, and we hope it becomes smart enough to enable breakthroughs."
JPMorgan Chase said that driven by technological advances, policy incentives, and capital investment, the development of AI in China's healthcare industry has been strong over the past five years. The deal reached by Insilico Medicine indicates that China's biotechnology AI capabilities have gained global recognition. (Translated by Zhu Li)
Original: https://www.toutiao.com/article/7521180268196086272/
Statement: This article represents the views of the author. Please express your opinion by clicking on the 【up/down】 buttons below.